Kadima's Psilocybin for Depression Study

Kadima is enrolling for a study investigating Psilocybin (COMP360) as a treatment for Major Depressive Disorder (MDD).

Please complete this short survey to determine your pre-eligibility

COMP Study

This study is sponsored by Compass Pathways. The Principal Investigator is David Feifel, MD, PhD. 

Scroll to Top